Market News & Trends
George Clinical Recruits More than 5,000 Patients in the Global Kidney Patient Trials Network
George Clinical, in close collaboration with The George Institute for Global Health, recently announced the recruitment of more than 5,000 patients in its ground-breaking, first…
Lonza Expands Global Process Development Team & Laboratory Spaces for Cell & Gene Development
Lonza recently announced it is expanding its cell and gene therapies (CGT) process and analytical development laboratories at its locations in Houston, TX, and Geleen…
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease
Phathom Pharmaceuticals, Inc. recently announced it has completed enrollment in its PHALCON-NERD Daily Dosing Phase 3 trial of vonoprazan in non-erosive gastroesophageal reflux disease (NERD).…
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections From Ongoing Phase 3 Study
SCYNEXIS, Inc. recently announced the presentation of cumulative interim outcomes and all-cause mortality data in patients with refractory candidiasis treated with oral ibrexafungerp from the…
Taconic Biosciences Launches First & Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors for Improved Antibody Therapy Assessment
Taconic Biosciences has recently launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcγRs) known…
Catalent Expands Biologics Analytical Capabilities With New Laboratories at Center of Excellence in Kansas City, MO
Catalent recently announced a $12-million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, MO. The project will see…
Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
Comera Life Sciences Holdings, Inc. recently announced favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study, the preclinical results showed that Comera’s…
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating Treatment of B-cell Acute Lymphoblastic Leukemia
Gracell Biotechnologies Inc. recently announced the first patient has been dosed in the Phase 2 portion of its registrational Phase 1/2 clinical trial evaluating GC007g…
Bora Pharmaceutical Makes Strategic Appointment to Strengthen Global Manufacturing Capabilities
Bora Pharmaceuticals, a full-service contract development and manufacturing organization (CDMO), recently appointed Don Liscombe as its Vice President and General Manager to lead its flagship…
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
PTC Therapeutics, Inc. recently announced enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington's disease at…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….